Effect of Fluoxetine and Escitalopram on Heart Rate Variability (HRV) and Serum Potassium Level in Patients of Depression and Anxiety Disorders

Truptiben R Machhi, Chetna R. Patel, Sajal K. Pandya, N. Kantharia
{"title":"Effect of Fluoxetine and Escitalopram on Heart Rate Variability (HRV) and Serum Potassium Level in Patients of Depression and Anxiety Disorders","authors":"Truptiben R Machhi, Chetna R. Patel, Sajal K. Pandya, N. Kantharia","doi":"10.1177/0976500x231213153","DOIUrl":null,"url":null,"abstract":"The present study was conducted to generate data regarding the effect of fluoxetine as an anti-depressant and escitalopram as an antianxiety agent on heart rate variability (HRV). There is a scarcity of data regarding the correlation between selective serotonin reuptake inhibitors (SSRIs) and serum potassium levels. To find out the effect of SSRIs on HRV, and whether it is either dependent or independent of serum potassium level. In this prospective, open-label, observational study, 70 participants were enrolled and divided into two groups, the fluoxetine group ( n = 35) and the escitalopram group ( n = 35) suffering from depression and anxiety, respectively. Parameters, like HRV, serum potassium level, heart rate, respiratory rate, and blood pressure, were measured baseline and after the first, second, and third months of treatment. HRV was calculated by root mean square deviation of successive differences between adjacent RR intervals (RMSSD). ECG (electrocardiogram) was recorded by Physio Pac Digital Polygraph software. All values were expressed as mean ± SD, and statistical analysis was done by using the repeated measure analysis of variance (ANOVA) test with Greenhouse–Geisser correction, post-hoc analysis with Bonferroni correction, and SPSS 20.0 software. Among a total of 70 participants, post-hoc tests using the Bonferroni correction showed a statistically significant difference between the HRV of the pretreatment group and after the second, and third month of fluoxetine therapy ( p < .05). In the escitalopram group, the Bonferroni correction showed a significant difference between the HRV of the pretreatment and third-month value ( p < .05). Repeated measure ANOVA with Greenhouse–Geisser correction showed no statistical significance of serum potassium at different time points ( p > .05). There were also no significant changes in heart rate, respiratory rate, and blood pressure at different points of time in both groups. Pearson’s correlation coefficient test for a relationship between HRV and serum potassium was negative at different time points. Fluoxetine significantly increased HRV from the pretreatment value to the second and third months of treatment, whereas in the escitalopram group of participants, the third-month value of HRV was increased compared to the first month. The effect of SSRIs on HRV was independent of serum potassium levels at different time points suggesting that the effect of SSRIs on HRV was independent of serum potassium level.","PeriodicalId":16780,"journal":{"name":"Journal of Pharmacology and Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0976500x231213153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The present study was conducted to generate data regarding the effect of fluoxetine as an anti-depressant and escitalopram as an antianxiety agent on heart rate variability (HRV). There is a scarcity of data regarding the correlation between selective serotonin reuptake inhibitors (SSRIs) and serum potassium levels. To find out the effect of SSRIs on HRV, and whether it is either dependent or independent of serum potassium level. In this prospective, open-label, observational study, 70 participants were enrolled and divided into two groups, the fluoxetine group ( n = 35) and the escitalopram group ( n = 35) suffering from depression and anxiety, respectively. Parameters, like HRV, serum potassium level, heart rate, respiratory rate, and blood pressure, were measured baseline and after the first, second, and third months of treatment. HRV was calculated by root mean square deviation of successive differences between adjacent RR intervals (RMSSD). ECG (electrocardiogram) was recorded by Physio Pac Digital Polygraph software. All values were expressed as mean ± SD, and statistical analysis was done by using the repeated measure analysis of variance (ANOVA) test with Greenhouse–Geisser correction, post-hoc analysis with Bonferroni correction, and SPSS 20.0 software. Among a total of 70 participants, post-hoc tests using the Bonferroni correction showed a statistically significant difference between the HRV of the pretreatment group and after the second, and third month of fluoxetine therapy ( p < .05). In the escitalopram group, the Bonferroni correction showed a significant difference between the HRV of the pretreatment and third-month value ( p < .05). Repeated measure ANOVA with Greenhouse–Geisser correction showed no statistical significance of serum potassium at different time points ( p > .05). There were also no significant changes in heart rate, respiratory rate, and blood pressure at different points of time in both groups. Pearson’s correlation coefficient test for a relationship between HRV and serum potassium was negative at different time points. Fluoxetine significantly increased HRV from the pretreatment value to the second and third months of treatment, whereas in the escitalopram group of participants, the third-month value of HRV was increased compared to the first month. The effect of SSRIs on HRV was independent of serum potassium levels at different time points suggesting that the effect of SSRIs on HRV was independent of serum potassium level.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
氟西汀和艾司西酞普兰对抑郁和焦虑症患者心率变异性(HRV)和血清钾水平的影响
本研究旨在获得有关抗抑郁药氟西汀和抗焦虑药艾司西酞普兰对心率变异性(HRV)影响的数据。有关选择性 5-羟色胺再摄取抑制剂(SSRIs)与血清钾水平之间相关性的数据很少。为了了解 SSRIs 对心率变异的影响,以及这种影响是依赖于血清钾水平还是独立于血清钾水平。在这项前瞻性、开放标签、观察性研究中,70 名参与者被分为两组,氟西汀组(35 人)和艾司西酞普兰组(35 人),他们分别患有抑郁症和焦虑症。对心率变异、血清钾水平、心率、呼吸频率和血压等参数进行了基线测量,并在治疗第一、第二和第三个月后进行了测量。心率变异按相邻 RR 间期连续差值的均方根偏差(RMSSD)计算。心电图(ECG)由 Physio Pac Digital Polygraph 软件记录。所有数值均以均数±标准差表示,统计分析采用重复测量方差分析(ANOVA)检验并进行格林豪斯-盖瑟尔校正,事后分析并进行邦费罗尼校正,以及 SPSS 20.0 软件。在总共 70 名参与者中,使用 Bonferroni 校正进行的事后检验显示,治疗前组与氟西汀治疗第二和第三个月后的心率变异之间存在显著的统计学差异(P < .05)。在艾司西酞普兰组,Bonferroni 校正显示治疗前和第三个月的心率变异值之间存在显著差异(P < .05)。经格林豪斯-盖瑟尔校正的重复测量方差分析显示,不同时间点的血清钾没有统计学意义(P > .05)。两组患者在不同时间点的心率、呼吸频率和血压也没有明显变化。不同时间点心率变异与血清钾之间的皮尔逊相关系数检验结果均为负。氟西汀能明显增加心率变异从治疗前值到治疗后第二和第三个月的值,而在艾司西酞普兰组的参与者中,第三个月的心率变异值比第一个月有所增加。SSRIs对心率变异的影响与不同时间点的血清钾水平无关,这表明SSRIs对心率变异的影响与血清钾水平无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Embodiment of Pharmacist Intervention in Palliative Care and Augmentation of a Curriculum for Its Assessment Future of Pharmaceutical Industry: Role of Artificial Intelligence, Automation, and Robotics Pharmacodynamic Interaction of Areca catechu with Gliclazide in Wistar Rats Mechanistic Roles of Different Varieties of Honey on Wound Healing: Recent Update Modulation of Stem Cell Factor by Forskolin Inhibits the Progression of Tubule Interstitial Fibrosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1